These results showed that AF is an independent risk factor for MI , CV death , and CV events
This study aim ed to investigate whether  atrial fibrillation ( AF ) predicts myocardial infa rct ion ( MI ) or cardiovascular ( CV ) death .
AF is a well-established risk factor for thrombotic stroke and all-cause mortality .
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
Background — There is a modest risk of myocardial infa rct ion ( MI )  and myocardial ischemic events in patients with atrial fibrillation . Methods and Results — Data from the RE-LY study ( R and omized Evaluation of Long-Term Anticoagulation Therapy ) were used to report rates of MI , unstable angina , cardiac arrest , and cardiac death and the prespecified net clinical benefit and treatment effects of dabigatran versus warfarin .  MI occurred at annual rates of 0.82 % and 0.81 % with dabigatran 110 or 150 mg BID compared with 0.64 % with warfarin ( hazard ratio [ HR ] 1.29 , 95 % confidence interval [ CI ] 0.96–1.75 , P=0.09 for dabigatran 110 mg ; HR 1.27 , 95 % CI 0.94–1.71 , P=0.12 for dabigatran 150 mg ) . Annual rates of a composite of MI , unstable angina , cardiac arrest , and cardiac death were 3.16 % per year with dabigatran 110 mg , 3.33 % per year with dabigatran 150 mg , and 3.41 % per year with warfarin ( HR versus warfarin 0.93 , 95 % CI 0.80–1.06 , P=0.28 for dabigatran 110 mg and HR 0.98 , 95 % CI 0.85–1.12 , P=0.77 for dabigatran 150 mg ) . Events prespecified as “ net clinical benefit ” ( all strokes , systemic embolism , MI , pulmonary embolism , major bleeding , and all-cause death ) occurred at a rate of 7.34 % per year with dabigatran 110 mg , 7.11 % per year with dabigatran 150 mg , and 7.91 % per year with warfarin ( HR 0.92 , 95 % CI 0.84–1.01 , P=0.09 for dabigatran 110 mg and HR 0.90 , 95 % CI 0.82–0.99 , P=0.02 for dabigatran 150 mg ) . The relative effects of dabigatran versus warfarin on myocardial ischemic events were consistent in patients with or without a baseline history of MI or coronary artery disease . Conclusions — There was a nonsignificant increase in MI with dabigatran compared with warfarin , but other myocardial ischemic events were not increased . Treatment effects of dabigatran were consistent in patients at higher and lower risk of myocardial ischemic events . Clinical Trial Registration — URL : http://www . clinical trials.gov . Unique identifier : NCT 00262600
These results showed that AF is an independent risk factor for MI , CV death , and CV events
This study aim ed to investigate whether  atrial fibrillation ( AF ) predicts myocardial infa rct ion ( MI ) or cardiovascular ( CV ) death .
AF is a well-established risk factor for thrombotic stroke and all-cause mortality .